REFERENCES
1. Tokarz VL, MacDonald PE, Klip A. The cell biology of systemic insulin function. J Cell Biol. 2018;217:2273-89.
2. Norton L, Shannon C, Gastaldelli A, DeFronzo RA. Insulin: the master regulator of glucose metabolism. Metabolism. 2022;129:155142.
3. Vogt ÉL, Kowaltowski AJ. GLP-1, Pancreatic β-cells, and insulin secretion: what we know and where we need to go. Diabetes. 2026;75:403-13.
4. Richter EA, Bilan PJ, Klip A. A comprehensive view of muscle glucose uptake: regulation by insulin, contractile activity, and exercise. Physiol Rev. 2025;105:1867-945.
5. Najjar SM, Caprio S, Gastaldelli A. Insulin clearance in health and disease. Annu Rev Physiol. 2023;85:363-81.
6. Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
7. American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care. 2026;49:S183-215.
8. Bo T, Gao L, Yao Z, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2024;36:947-68.
9. Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013;9:25-53.
10. Lee K, Cho H, Rickert RW, et al. FOXA2 is required for enhancer priming during pancreatic differentiation. Cell Rep. 2019;28:382-93.e7.
11. Geusz RJ, Wang A, Lam DK, et al. Sequence logic at enhancers governs a dual mechanism of endodermal organ fate induction by FOXA pioneer factors. Nat Commun. 2021;12:6636.
12. Schaffer AE, Taylor BL, Benthuysen JR, et al. Nkx6.1 controls a gene regulatory network required for establishing and maintaining pancreatic Beta cell identity. PLoS Genet. 2013;9:e1003274.
13. Zhu Y, Liu Q, Zhou Z, Ikeda Y. PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration. Stem Cell Res Ther. 2017;8:240.
14. Son J, Accili D. Reversing pancreatic β-cell dedifferentiation in the treatment of type 2 diabetes. Exp Mol Med. 2023;55:1652-8.
15. Jeyagaran A, Urbanczyk M, Layland SL, Weise F, Schenke-Layland K. Forward programming of hiPSCs towards beta-like cells using Ngn3, Pdx1, and MafA. Sci Rep. 2024;14:13608.
16. Patel S, Remedi MS. Loss of β-cell identity and dedifferentiation, not an irreversible process? Front Endocrinol 2024;15:1414447.
17. Tang X, Kuo T, Wei Z. Editorial: pancreatic beta-cell dedifferentiation. Front Endocrinol. 2024;15:1524001.
18. Chen K, Zhang J, Huang Y, Tian X, Yang Y, Dong A. Single-cell RNA-seq transcriptomic landscape of human and mouse islets and pathological alterations of diabetes. iScience. 2022;25:105366.
19. Yang BT, Dayeh TA, Volkov PA, et al. Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes. Mol Endocrinol. 2012;26:1203-12.
20. Kim H, Kulkarni RN. Epigenetics in β-cell adaptation and type 2 diabetes. Curr Opin Pharmacol. 2020;55:125-31.
21. Aigha II, Abdelalim EM. NKX6.1 transcription factor: a crucial regulator of pancreatic β cell development, identity, and proliferation. Stem Cell Res Ther. 2020;11:459.
22. Taylor BL, Liu FF, Sander M. Nkx6.1 is essential for maintaining the functional state of pancreatic beta cells. Cell Rep. 2013;4:1262-75.
23. Matsuoka TA, Artner I, Henderson E, Means A, Sander M, Stein R. The MafA transcription factor appears to be responsible for tissue-specific expression of insulin. Proc Natl Acad Sci U S A. 2004;101:2930-3.
24. Guo QS, Zhu MY, Wang L, et al. Combined transfection of the three transcriptional factors, PDX-1, NeuroD1, and MafA, causes differentiation of bone marrow mesenchymal stem cells into insulin-producing cells. Exp Diabetes Res. 2012;2012:672013.
25. Liu XD, Ruan JX, Xia JH, Yang SL, Fan JH, Li K. The study of regulatory effects of Pdx-1, MafA and NeuroD1 on the activity of porcine insulin promoter and the expression of human islet amyloid polypeptide. Mol Cell Biochem. 2014;394:59-66.
26. Liang J, Chirikjian M, Pajvani UB, Bartolomé A. MafA regulation in β-cells: from transcriptional to post-translational mechanisms. Biomolecules. 2022;12:535.
27. Hou N, Mogami H, Kubota-Murata C, Sun M, Takeuchi T, Torii S. Preferential release of newly synthesized insulin assessed by a multi-label reporter system using pancreatic β-cell line MIN6. PLoS One. 2012;7:e47921.
28. Sun J, Cui J, He Q, Chen Z, Arvan P, Liu M. Proinsulin misfolding and endoplasmic reticulum stress during the development and progression of diabetes. Mol Aspects Med. 2015;42:105-18.
29. Boyer CK, Bauchle CJ, Zhang J, Wang Y, Stephens SB. Synchronized proinsulin trafficking reveals delayed Golgi export accompanies β-cell secretory dysfunction in rodent models of hyperglycemia. Sci Rep. 2023;13:5218.
30. Cui D, Feng X, Lei S, et al. Pancreatic β-cell failure, clinical implications, and therapeutic strategies in type 2 diabetes. Chin Med J. 2024;137:791-805.
31. Zavarzadeh PG, Panchal K, Bishop D, et al. Exploring proinsulin proteostasis: insights into beta cell health and diabetes. Front Mol Biosci. 2025;12:1554717.
32. Wahren J, Kallas A, Sima AA. The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes. 2012;61:761-72.
33. Chen J, Huang Y, Liu C, Chi J, Wang Y, Xu L. The role of C-peptide in diabetes and its complications: an updated review. Front Endocrinol. 2023;14:1256093.
34. Arunagiri A, Haataja L, Pottekat A, et al. Proinsulin misfolding is an early event in the progression to type 2 diabetes. Elife. 2019;8:e44532.
35. Izumi T, Yokota-Hashimoto H, Zhao S, Wang J, Halban PA, Takeuchi T. Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. Diabetes. 2003;52:409-16.
36. Chen CW, Guan BJ, Alzahrani MR, et al. Adaptation to chronic ER stress enforces pancreatic β-cell plasticity. Nat Commun. 2022;13:4621.
37. Shrestha N, De Franco E, Arvan P, Cnop M. Pathological β-cell endoplasmic reticulum stress in type 2 diabetes: current evidence. Front Endocrinol. 2021;12:650158.
38. Diane A, Allouch A, Mu-U-Min RBA, Al-Siddiqi HH. Endoplasmic reticulum stress in pancreatic β-cell dysfunctionality and diabetes mellitus: a promising target for generation of functional hPSC-derived β-cells in vitro. Front Endocrinol. 2024;15:1386471.
39. An Y, Norris N, Li D, Gunton JE. Βeta-cells: stress, identity, failure and diabetes. Cells. 2026;15:475.
40. Zhang Y, Lin S, Yao J, et al. XBP1 splicing contributes to endoplasmic reticulum stress-induced human islet amyloid polypeptide up-regulation. Genes Dis. 2024;11:101148.
41. Yau B, Ghislain J, Kebede MA, Hughes J, Poitout V. The role of the beta cell in type 2 diabetes: new findings from the last 5 years. Diabetologia. 2025;68:2092-103.
42. Wat LW, Svensson KJ. Novel secreted regulators of glucose and lipid metabolism in the development of metabolic diseases. Diabetologia. 2024;67:2626-36.
43. Salvadó L, Barroso E, Gómez-Foix AM, et al. PPARβ/δ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia. 2014;57:2126-35.
44. Chen YC, Taylor AJ, Fulcher JM, et al. Deletion of carboxypeptidase E in β-cells disrupts proinsulin processing but does not lead to spontaneous development of diabetes in mice. Diabetes. 2023;72:1277-88.
45. Dror E, Fagnocchi L, Wegert V, et al. Epigenetic dosage identifies two major and functionally distinct β cell subtypes. Cell Metab. 2023;35:821-36.e7.
46. Rutter GA, Gresch A, Delgadillo Silva L, Benninger RKP. Exploring pancreatic beta-cell subgroups and their connectivity. Nat Metab. 2024;6:2039-53.
47. Hall E, Dekker Nitert M, Volkov P, et al. The effects of high glucose exposure on global gene expression and DNA methylation in human pancreatic islets. Mol Cell Endocrinol. 2018;472:57-67.
48. Dayeh T, Volkov P, Salö S, et al. Genome-Wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion. PLoS Genet. 2014;10:e1004160.
49. Rönn T, Ofori JK, Perfilyev A, et al. Genes with epigenetic alterations in human pancreatic islets impact mitochondrial function, insulin secretion, and type 2 diabetes. Nat Commun. 2023;14:8040.
50. Downing TL, Soto J, Morez C, et al. Biophysical regulation of epigenetic state and cell reprogramming. Nat Mater. 2013;12:1154-62.
52. Fernández-Díaz CM, Merino B, López-Acosta JF, et al. Pancreatic β-cell-specific deletion of insulin-degrading enzyme leads to dysregulated insulin secretion and β-cell functional immaturity. Am J Physiol Endocrinol Metab. 2019;317:E805-19.
53. De Vos A, Heimberg H, Quartier E, et al. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest. 1995;96:2489-95.
55. Rorsman P, Ashcroft FM. Pancreatic β-cell electrical activity and insulin secretion: of mice and men. Physiol Rev. 2018;98:117-214.
56. Deepa Maheshvare M, Raha S, König M, Pal D. A pathway model of glucose-stimulated insulin secretion in the pancreatic β-cell. Front Endocrinol. 2023;14:1185656.
57. Muñoz F, Fex M, Moritz T, Mulder H, Cataldo LR. Unique features of β-cell metabolism are lost in type 2 diabetes. Acta Physiol. 2024;240:e14148.
58. Merrins MJ, Corkey BE, Kibbey RG, Prentki M. Metabolic cycles and signals for insulin secretion. Cell Metab. 2022;34:947-68.
59. Foster HR, Ho T, Potapenko E, et al. β-cell deletion of the PKm1 and PKm2 isoforms of pyruvate kinase in mice reveals their essential role as nutrient sensors for the K(ATP) channel. Elife. 2022;11:e79422.
60. Rutter GA, Hodson DJ, Chabosseau P, Haythorne E, Pullen TJ, Leclerc I. Local and regional control of calcium dynamics in the pancreatic islet. Diabetes Obes Metab. 2017;19:30-41.
61. Young KG, McInnes EH, Massey RJ, et al. ; ADA/EASD PDMI. Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review. Commun Med. 2023;3:131.
62. Cardoso P, Young KG, Nair ATN, et al. ; MASTERMIND consortium. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Diabetologia. 2024;67:822-36.
63. Trapanese V, Dagostino A, Natale MR, et al. Bidirectional interactions between the gut microbiota and incretin-based therapies. Life. 2025;15:843.
64. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes. 2005;54:1649-56.
66. Miranda MA, Macias-Velasco JF, Lawson HA. Pancreatic β-cell heterogeneity in health and diabetes: classes, sources, and subtypes. Am J Physiol Endocrinol Metab. 2021;320:E716-31.
68. Zabuliene L, Ilias I. Epinephrine also acts on beta cells and insulin secretion. World J Clin Cases. 2024;12:1712-3.
69. Dalle S, Abderrahmani A. Receptors and signaling pathways controlling beta-cell function and survival as targets for anti-diabetic therapeutic strategies. Cells. 2024;13:1244.
70. Zhang Y, Han C, Zhu W, et al. Glucagon potentiates insulin secretion via β-cell GCGR at physiological concentrations of glucose. Cells. 2021;10:2495.
71. Shuai H, Xu Y, Ahooghalandari P, Tengholm A. Glucose-induced cAMP elevation in β-cells involves amplification of constitutive and glucagon-activated GLP-1 receptor signalling. Acta Physiol. 2021;231:e13611.
72. El K, Douros JD, Willard FS, et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat Metab. 2023;5:945-54.
73. Barmaver SN, Gu G, Kaverina I. Roles of molecular motors in insulin-secreting beta cells. Curr Opin Cell Biol. 2025;97:102582.
74. Zhu X, Hu R, Brissova M, et al. Microtubules negatively regulate insulin secretion in pancreatic β cells. Dev Cell. 2015;34:656-68.
75. Li W, Li A, Yu B, et al. In situ structure of actin remodeling during glucose-stimulated insulin secretion using cryo-electron tomography. Nat Commun. 2024;15:1311.
76. Hughes JW, Cho JH, Conway HE, et al. Primary cilia control glucose homeostasis via islet paracrine interactions. Proc Natl Acad Sci U S A. 2020;117:8912-23.
77. Müller A, Klena N, Pang S, et al. Structure, interaction and nervous connectivity of beta cell primary cilia. Nat Commun. 2024;15:9168.
78. Gerdes JM, Christou-Savina S, Xiong Y, et al. Ciliary dysfunction impairs beta-cell insulin secretion and promotes development of type 2 diabetes in rodents. Nat Commun. 2014;5:5308.
79. Kluth O, Stadion M, Gottmann P, et al. Decreased expression of Cilia genes in pancreatic islets as a risk factor for type 2 diabetes in mice and humans. Cell Rep. 2019;26:3027-36.e3.
80. Najjar SM, Perdomo G. Hepatic insulin clearance: mechanism and physiology. Physiology. 2019;34:198-215.
81. Rubio-Navarro A, Gómez-Banoy N, Stoll L, et al. A beta cell subset with enhanced insulin secretion and glucose metabolism is reduced in type 2 diabetes. Nat Cell Biol. 2023;25:565-78.
82. Peng X, Ren H, Yang L, et al. Readily releasable β cells with tight Ca2+-exocytosis coupling dictate biphasic glucose-stimulated insulin secretion. Nat Metab. 2024;6:238-53.
83. Zhang Z, Wang S, Gao L. Circadian rhythm, glucose metabolism and diabetic complications: the role of glucokinase and the enlightenment on future treatment. Front Physiol. 2025;16:1537231.
84. Grasset E, Puel A, Charpentier J, et al. Gut microbiota dysbiosis of type 2 diabetic mice impairs the intestinal daily rhythms of GLP-1 sensitivity. Acta Diabetol. 2022;59:243-58.
85. Xing J, Chen C. Hyperinsulinemia: beneficial or harmful or both on glucose homeostasis. Am J Physiol Endocrinol Metab. 2022;323:E2-7.
86. Dahiya R, Singh AP, Rawat A. Immunometabolic reprogramming and β-cell dedifferentiation: integrated mechanisms driving type 2 diabetes progression. Diabetes Res Clin Pract. 2026;232:113111.
87. Ren H, Li Y, Xie B, et al. Pancreatic islet oscillation rhythmicity arises from δ and α cell interactions. Cell Syst. 2026;17:101587.
88. Abe I, Islam F, Lam AK. Glucose intolerance on phaeochromocytoma and paraganglioma-the current understanding and clinical perspectives. Front Endocrinol. 2020;11:593780.
89. Zhang W, Yu J, Chen Y, et al. Glucose disorders in patients with pheochromocytoma/paraganglioma: profile and influence effects in a large cohort with 705 patients. Endocr Pract. 2025;31:269-77.
90. DeFronzo RA, Auchus RJ. Cushing syndrome, hypercortisolism, and glucose homeostasis: a review. Diabetes. 2025;74:2168-78.
91. Janssen JAMJL. Hyperinsulinemia and its pivotal role in aging, obesity, type 2 diabetes, cardiovascular disease and cancer. Int J Mol Sci. 2021;22:7797.
92. Peng H, Wang M, Guo H, et al. Parental transmission of type 2 diabetes risk in offspring: a prospective family-based cohort study in northern China. Nutrients. 2025;17:1361.
93. Cao Y, Xu R, Zhang J. Insulin resistance in obese children and adolescents: from mechanisms to screening and exercise intervention. Front Pediatr. 2026;14:1679527.
94. Gϋemes M, Rahman SA, Kapoor RR, et al. Hyperinsulinemic hypoglycemia in children and adolescents: recent advances in understanding of pathophysiology and management. Rev Endocr Metab Disord. 2020;21:577-97.
95. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34:1878-84.
96. Tosur M, Philipson LH. Precision diabetes: lessons learned from maturity-onset diabetes of the young (MODY). J Diabetes Investig. 2022;13:1465-71.
97. Stankute I, Dobrovolskiene R, Danyte E, Steponaviciute R, Schwitzgebel VM, Verkauskiene R. Pancreatic beta-cell function dynamics in youth with GCK, HNF1A, and KCNJ11 genes mutations during mixed meal tolerance test. Pediatr Diabetes. 2022;23:1009-16.
98. Bowman P, Sulen Å, Barbetti F, et al.; Neonatal Diabetes International Collaborative Group. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. Lancet Diabetes Endocrinol. 2018;6:637-46.
99. Lee MY, Gloyn AL, Maahs DM, Prahalad P. Management of neonatal diabetes due to a KCNJ11 mutation with automated insulin delivery system and remote patient monitoring. Case Rep Endocrinol. 2023;2023:8825724.
100. Zhang H, Yuan MX, Pan Q. Insulin autoimmune syndrome: a chinese expert consensus statement. Aging Med. 2025;8:e70007.
101. Zhang Z, He X, Sun Y, Li J, Sun J. Type 2 diabetes mellitus: a metabolic model of accelerated aging - multi-organ mechanisms and intervention approaches. Aging Dis. 2025;17:1399-422.
102. Brown LR. Whipple’s triad: the often-overshadowed legacy of Allen Oldfather Whipple. Br J Surg. 2021;108:e76.
103. Gao Y, Wang N, Huang Z, Bai N. Exogenous insulin autoimmune syndrome: a case report and literature review. Front Endocrinol. 2025;16:1700742.
104. Sidrak MMA, De Feo MS, Corica F, et al. Role of exendin-4 functional imaging in diagnosis of insulinoma: a systematic review. Life. 2023;13:989.
105. Salehi M, Peterson R, Tripathy D, Pezzica S, DeFronzo R, Gastaldelli A. Differential effect of gastric bypass versus sleeve gastrectomy on insulinotropic action of endogenous incretins. Obesity. 2023;31:2774-85.
106. Rayas M, Pezzica S, Honka H, et al. GLP-1 enhances β-cell response to protein ingestion and bariatric surgery amplifies it. Obesity. 2025;33:104-15.
107. Dawes D, Trivedi P, Lawler H. Nesidioblastosis in patients with severe postbariatric hypoglycemia: a monocentric case series. J Endocr Soc. 2025;9:bvaf125.
108. Dieterle MP, Husari A, Prozmann SN, et al. Diffuse, adult-onset nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): review of the literature of a rare cause of hyperinsulinemic hypoglycemia. Biomedicines. 2023;11:1732.
109. Ramos-Cardona JC, Rafiq M, Quinn Martinez S. Noninsulinoma hyperinsulinemic hypoglycemia syndrome emerging post-nissen fundoplication. JCEM Case Rep. 2026;4:luaf326.
110. Houston EJ, Templeman NM. Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS. J Endocrinol. 2025;265:e240269.
111. Topsakal Ş, Yaylalı GF, Yarar Z, et al. Multicenter study on the clinical characteristics, diagnosis, and treatment outcomes of insulinoma: insights from 15 medical centres. Clin Endocrinol. 2025;103:57-65.
112. Church D, Cardoso L, Kay RG, et al. Assessment and management of anti-insulin autoantibodies in varying presentations of insulin autoimmune syndrome. J Clin Endocrinol Metab. 2018;103:3845-55.
113. Lin M, Chen Y, Ning J. Insulin autoimmune syndrome: a systematic review. Int J Endocrinol. 2023;2023:1225676.
114. Garcin L, Mericq V, Fauret-Amsellem AL, Cave H, Polak M, Beltrand J. Neonatal diabetes due to potassium channel mutation: response to sulfonylurea according to the genotype. Pediatr Diabetes. 2020;21:932-41.
115. Yavas Abali Z, Bas F, Houghton JAL, et al. Comprehensive clinical and molecular characterization with long-term outcomes in 40 patients with congenital hyperinsulinism. Endocrine. 2025;89:416-28.
116. Ghadieh HE, Gastaldelli A, Najjar SM. Role of insulin clearance in insulin action and metabolic diseases. Int J Mol Sci. 2023;24:7156.
117. Lee WH, Najjar SM, Kahn CR, Hinds TD Jr. Hepatic insulin receptor: new views on the mechanisms of liver disease. Metabolism. 2023;145:155607.
118. Truong XT, Lee DH. Hepatic insulin resistance and steatosis in metabolic dysfunction-associated steatotic liver disease: new insights into mechanisms and clinical implications. Diabetes Metab J. 2025;49:964-86.
119. Grazia Revello M, Percivalle E, Zannino M, Rossi V, Gerna G. Development and evaluation of a capture ELISA for IgM antibody to the human cytomegalovirus major DNA binding protein. J Virol Methods. 1991;35:315-29.
120. DeAngelis AM, Heinrich G, Dai T, et al. Carcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism. Diabetes. 2008;57:2296-303.
121. Parvathareddy VP, Wu J, Thomas SS. Insulin resistance and insulin handling in chronic kidney disease. Compr Physiol. 2023;13:5069-76.
122. van Baar MJB, van Bommel EJM, Smits MM, et al. Whole-body insulin clearance in people with type 2 diabetes and normal kidney function: Relationship with glomerular filtration rate, renal plasma flow, and insulin sensitivity. J Diabetes Complications. 2022;36:108166.
123. Meijer RI, Barrett EJ. The insulin receptor mediates insulin’s early plasma clearance by liver, muscle, and kidney. Biomedicines. 2021;9:37.
124. Lee CC, Haffner SM, Wagenknecht LE, et al. Insulin clearance and the incidence of type 2 diabetes in Hispanics and African Americans: the IRAS family study. Diabetes Care. 2013;36:901-7.
125. Polidori DC, Bergman RN, Chung ST, Sumner AE. Hepatic and extrahepatic insulin clearance are differentially regulated: results from a novel model-based analysis of intravenous glucose tolerance data. Diabetes. 2016;65:1556-64.
126. Ladwa M, Bello O, Hakim O, et al. Exploring the determinants of ethnic differences in insulin clearance between men of Black African and White European ethnicity. Acta Diabetol. 2022;59:329-37.
127. Fosam A, Sikder S, Abel BS, et al. Reduced insulin clearance and insulin-degrading enzyme activity contribute to hyperinsulinemia in African Americans. J Clin Endocrinol Metab. 2020;105:e1835-46.
128. Bojsen-Møller KN, Lundsgaard AM, Madsbad S, Kiens B, Holst JJ. Hepatic insulin clearance in regulation of systemic insulin concentrations-role of carbohydrate and energy availability. Diabetes. 2018;67:2129-36.
129. Asare-Bediako I, Paszkiewicz RL, Kim SP, et al. Variability of directly measured first-pass hepatic insulin extraction and its association with insulin sensitivity and plasma insulin. Diabetes. 2018;67:1495-503.
130. Zaidi S, Asalla S, Muturi HT, et al. Loss of CEACAM1 in hepatocytes causes hepatic fibrosis. Eur J Clin Invest. 2024;54:e14177.
131. Lee WH, Kipp ZA, Bates EA, Pauss SN, Martinez GJ, Hinds TD Jr. The physiology of MASLD: molecular pathways between liver and adipose tissues. Clin Sci. 2025;139:1015-46.
132. Edgerton DS, Moore MC, Gregory JM, Kraft G, Cherrington AD. Importance of the route of insulin delivery to its control of glucose metabolism. Am J Physiol Endocrinol Metab. 2021;320:E891-7.
133. Kraft G, Coate KC, Smith M, et al. Profound sensitivity of the liver to the direct effect of insulin allows peripheral insulin delivery to normalize hepatic but not muscle glucose uptake in the healthy dog. Diabetes. 2023;72:196-209.
134. Edgerton DS, Scott M, Farmer B, et al. Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery. JCI Insight. 2019;5:126974.
135. Rizza RA, Westland RE, Hall LD, et al. Effect of peripheral versus portal venous administration of insulin on postprandial hyperglycemia and glucose turnover in alloxan-diabetic dogs. Mayo Clin Proc. 1981;56:434-8.
136. Shao J, Zaro JL, Shen WC. Tissue barriers and novel approaches to achieve hepatoselectivity of subcutaneously-injected insulin therapeutics. Tissue Barriers. 2016;4:e1156804.
137. Arbit E, Kidron M. Oral insulin delivery in a physiologic context: review. J Diabetes Sci Technol. 2017;11:825-32.
138. Zhang Y, Zhou W, Shen L, et al. Safety, pharmacokinetics, and pharmacodynamics of oral insulin administration in healthy subjects: a randomized, double-blind, phase 1 trial. Clin Pharmacol Drug Dev. 2022;11:606-14.
139. Dirnena-Fusini I, Åm MK, Fougner AL, Carlsen SM, Christiansen SC. Physiological effects of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: a systematic review and meta-analysis. PLoS One. 2021;16:e0249611.
140. Schiavon M, Cobelli C, Dalla Man C. Modeling intraperitoneal insulin absorption in patients with type 1 diabetes. Metabolites. 2021;11:600.
141. Lo Presti J, Galderisi A, Doyle FJ 3rd, et al. Intraperitoneal insulin delivery: evidence of a physiological route for artificial pancreas from compartmental modeling. J Diabetes Sci Technol. 2023;17:751-6.
142. Dalla Libera A, Toffanin C, Drecogna M, Galderisi A, Pillonetto G, Cobelli C. In silico design and validation of a time-varying PID controller for an artificial pancreas with intraperitoneal insulin delivery and glucose sensing. APL Bioeng. 2023;7:026105.
143. Richter B, Bongaerts B, Metzendorf MI. Thermal stability and storage of human insulin. Cochrane Database Syst Rev. 2023;11:CD015385.
144. Sen S, Ali R, Onkar A, et al. Synthesis of a highly thermostable insulin by phenylalanine conjugation at B29 Lysine. Commun Chem. 2024;7:161.
145. Al-Share QY, DeAngelis AM, Lester SG, et al. Forced hepatic overexpression of CEACAM1 curtails diet-induced insulin resistance. Diabetes. 2015;64:2780-90.
146. Lee W. The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes. Diagn Pathol. 2011;6:40.
147. Muturi HT, Ghadieh HE, Abdolahipour R, et al. Loss of CEACAM1 in endothelial cells causes hepatic fibrosis. Metabolism. 2023;144:155562.
148. Patarrão RS, Meneses MJ, Ghadieh HE, et al. Insights into circulating CEACAM1 in insulin clearance and disease progression: evidence from the portuguese PREVADIAB2 study. Eur J Clin Invest. 2024;54:e14344.
149. Russo L, Ghadieh HE, Ghanem SS, et al. Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. J Lipid Res. 2016;57:2163-75.
150. Ghadieh HE, Muturi HT, Russo L, et al. Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis. Hepatol Commun. 2018;2:35-47.
151. Muturi HT, Ghadieh HE, Asalla S, et al. Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. Mol Metab. 2024;88:102010.
152. Najjar SM, Abdolahipour R, Ghadieh HE, et al. Regulation of insulin clearance by non-esterified fatty acids. Biomedicines. 2022;10:1899.
153. Soares GM, Lopes LES, Balbo SL, et al. Sleeve gastrectomy-induced weight loss increases insulin clearance in obese mice. Int J Mol Sci. 2023;24:1729.
154. Yildirim V, Ter Horst KW, Gilijamse PW, et al. Bariatric surgery improves postprandial VLDL kinetics and restores insulin-mediated regulation of hepatic VLDL production. JCI Insight. 2023;8:e166905.
155. Heinrich G, Muturi HT, Rezaei K, et al. Reduced hepatic carcinoembryonic antigen-related cell adhesion molecule 1 level in obesity. Front Endocrinol. 2017;8:54.
156. Wisløff U, Najjar SM, Ellingsen O, et al. Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. Science. 2005;307:418-20.
157. Bowman TA, Ramakrishnan SK, Kaw M, et al. Caloric restriction reverses hepatic insulin resistance and steatosis in rats with low aerobic capacity. Endocrinology. 2010;151:5157-64.
158. González-Casimiro CM, Merino B, Casanueva-Álvarez E, et al. Modulation of insulin sensitivity by insulin-degrading enzyme. Biomedicines. 2021;9:86.
159. Leissring MA, González-Casimiro CM, Merino B, Suire CN, Perdomo G. Targeting insulin-degrading enzyme in insulin clearance. Int J Mol Sci. 2021;22:2235.
160. Villa-Pérez P, Merino B, Fernández-Díaz CM, et al. Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice. Metabolism. 2018;88:1-11.
161. Merino B, Fernández-Díaz CM, Parrado-Fernández C, et al. Hepatic insulin-degrading enzyme regulates glucose and insulin homeostasis in diet-induced obese mice. Metabolism. 2020;113:154352.
162. Borges DO, Patarrão RS, Ribeiro RT, et al. Loss of postprandial insulin clearance control by Insulin-degrading enzyme drives dysmetabolism traits. Metabolism. 2021;118:154735.
163. Maianti JP, McFedries A, Foda ZH, et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 2014;511:94-8.
164. Fursht O, Liran M, Nash Y, et al. Antibody-mediated inhibition of insulin-degrading enzyme improves insulin activity in a diabetic mouse model. Front Immunol. 2022;13:835774.
165. Durham TB, Toth JL, Klimkowski VJ, et al. Dual exosite-binding inhibitors of insulin-degrading enzyme challenge its role as the primary mediator of insulin clearance in vivo. J Biol Chem. 2015;290:20044-20059.
166. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003;100:4162-7.
167. Abdul-Hay SO, Kang D, McBride M, Li L, Zhao J, Leissring MA. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. PLoS One. 2011;6:e20818.
168. Sanz-González A, Cózar-Castellano I, Broca C, et al. Pharmacological activation of insulin-degrading enzyme improves insulin secretion and glucose tolerance in diet-induced obese mice. Diabetes Obes Metab. 2023;25:3268-78.
169. Kraupner N, Dinh CP, Wen X, et al. Identification of indole-based activators of insulin degrading enzyme. Eur J Med Chem. 2022;228:113982.
170. Ohgusu Y, Ohta KY, Ishii M, et al. Functional characterization of human aquaporin 9 as a facilitative glycerol carrier. Drug Metab Pharmacokinet. 2008;23:279-84.
171. Jelen S, Wacker S, Aponte-Santamaría C, et al. Aquaporin-9 protein is the primary route of hepatocyte glycerol uptake for glycerol gluconeogenesis in mice. J Biol Chem. 2011;286:44319-25.
172. Calamita G, Gena P, Ferri D, et al. Biophysical assessment of aquaporin-9 as principal facilitative pathway in mouse liver import of glucogenetic glycerol. Biol Cell. 2012;104:342-51.
173. Rodríguez A, Catalán V, Gómez-Ambrosi J, Frühbeck G. Aquaglyceroporins serve as metabolic gateways in adiposity and insulin resistance control. Cell Cycle. 2011;10:1548-56.
174. Rodríguez A, Gena P, Méndez-Giménez L, et al. Reduced hepatic aquaporin-9 and glycerol permeability are related to insulin resistance in non-alcoholic fatty liver disease. Int J Obes. 2014;38:1213-20.
175. Li Calzi S, Choice CV, Najjar SM. Differential effect of pp120 on insulin endocytosis by two variant insulin receptor isoforms. Am J Physiol. 1997;273:E801-8.
176. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 2002;283:E413-22.
178. Taheri R, Mokhtari Y, Yousefi AM, Bashash D. The PI3K/Akt signaling axis and type 2 diabetes mellitus (T2DM): from mechanistic insights into possible therapeutic targets. Cell Biol Int. 2024;48:1049-68.
179. Lewis GF, Carpentier AC, Pereira S, Hahn M, Giacca A. Direct and indirect control of hepatic glucose production by insulin. Cell Metab. 2021;33:709-20.
180. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785-9.
181. Miao R, Fang X, Wei J, Wu H, Wang X, Tian J. Akt: a potential drug target for metabolic syndrome. Front Physiol. 2022;13:822333.
182. Jiang S, Zhai L, Shao Y, Sun F, Liu X. Targeting the PI3K/AKT signaling pathway: an important molecular mechanism of herbal medicine in the treatment of MASLD/MASH. Front Nutr. 2025;12:1743899.
183. DiPilato LM, Ahmad F, Harms M, Seale P, Manganiello V, Birnbaum MJ. The role of PDE3B phosphorylation in the inhibition of lipolysis by insulin. Mol Cell Biol. 2015;35:2752-60.
184. Creasy KT, Mehta MB, Schneider CV, et al. Ppp1r3b is a metabolic switch that shifts hepatic energy storage from lipid to glycogen. Sci Adv. 2025;11:eado3440.
185. Okuma H, Tsuchiya K. Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders. Pharmacol Ther. 2024;262:108699.
186. Yokoyama A, Suzuki S, Okamoto K, Sugawara A. The physiological and pathophysiological roles of carbohydrate response element binding protein in the kidney. Endocr J. 2022;69:605-12.
187. Li Y, Wu S, Zhao X, et al. Key events in cancer: dysregulation of SREBPs. Front Pharmacol. 2023;14:1130747.
188. Li B, Piao S, Fu Y, et al. Lipid metabolism-MAFLD crosstalk: mechanisms and therapy. Front Endocrinol. 2026;17:1785178.
189. Kamagate A, Qu S, Perdomo G, et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest. 2008;118:2347-64.
190. Carli F, Della Pepa G, Sabatini S, Vidal Puig A, Gastaldelli A. Lipid metabolism in MASLD and MASH: from mechanism to the clinic. JHEP Rep. 2024;6:101185.
191. Palomurto S, Virtanen KA, Kärjä V, et al. Metabolic dysfunction-associated steatotic liver disease alters fatty acid profiles in the liver and adipose tissue. J Clin Endocrinol Metab. 2025;111:e23-31.
192. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98:2133-223.
193. Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022;46:15-37.
194. Accili D, Deng Z, Liu Q. Insulin resistance in type 2 diabetes mellitus. Nat Rev Endocrinol. 2025;21:413-26.
195. da Silva Rosa SC, Nayak N, Caymo AM, Gordon JW. Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue. Physiol Rep. 2020;8:e14607.
196. Wasserman DH. Insulin, muscle glucose uptake, and hexokinase: revisiting the road not taken. Physiology. 2022;37:115-27.
197. Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K/Akt pathway and glucose metabolism: a dangerous liaison in cancer. Int J Biol Sci. 2024;20:3113-25.
198. Kumar V, Greenberg ML. Emerging roles of pyruvate dehydrogenase phosphatase 1: a key player in metabolic health. Front Physiol. 2025;16:1596636.
199. Szwed A, Kim E, Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev. 2021;101:1371-426.
200. Chen K, Gao P, Li Z, et al. Forkhead Box O signaling pathway in skeletal muscle atrophy. Am J Pathol. 2022;192:1648-57.
201. Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, et al. The role of adipokines in health and disease. Biomedicines. 2023;11:1290.
202. Santoro A, McGraw TE, Kahn BB. Insulin action in adipocytes, adipose remodeling, and systemic effects. Cell Metab. 2021;33:748-57.
203. Li Y, Li Z, Ngandiri DA, Llerins Perez M, Wolf A, Wang Y. The molecular brakes of adipose tissue lipolysis. Front Physiol. 2022;13:826314.
204. Savova MS, Mihaylova LV, Tews D, Wabitsch M, Georgiev MI. Targeting PI3K/AKT signaling pathway in obesity. Biomed Pharmacother. 2023;159:114244.
205. Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol. 2017;13:710-30.
206. Galli M, Hameed A, Żbikowski A, Zabielski P. Aquaporins in insulin resistance and diabetes: more than channels! Redox Biol 2021;44:102027.
207. Ferré P, Phan F, Foufelle F. SREBP-1c and lipogenesis in the liver: an update1. Biochem J. 2021;478:3723-39.
208. Mitchell CS, Begg DP. The regulation of food intake by insulin in the central nervous system. J Neuroendocrinol. 2021;33:e12952.
209. Kullmann S, Blum D, Jaghutriz BA, et al. Central insulin modulates dopamine signaling in the human striatum. J Clin Endocrinol Metab. 2021;106:2949-61.
210. Chen W, Cai W, Hoover B, Kahn CR. Insulin action in the brain: cell types, circuits, and diseases. Trends Neurosci. 2022;45:384-400.
212. Pliszka M, Szablewski L. Insulin signaling in alzheimer's disease: association with brain insulin resistance. Int J Mol Sci. 2026;27:1222.
213. Martínez Báez A, Ayala G, Pedroza-Saavedra A, González-Sánchez HM, Chihu Amparan L. Phosphorylation codes in IRS-1 and IRS-2 are associated with the activation/inhibition of insulin canonical signaling pathways. Curr Issues Mol Biol. 2024;46:634-49.
214. Uehara K, Santoleri D, Whitlock AEG, Titchenell PM. Insulin regulation of hepatic lipid homeostasis. Compr Physiol. 2023;13:4785-809.
215. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes. 2006;55:2392-7.
216. Szendroedi J, Yoshimura T, Phielix E, et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc Natl Acad Sci U S A. 2014;111:9597-602.
217. Stocks B, Zierath JR. Post-translational modifications: the signals at the intersection of exercise, glucose uptake, and insulin sensitivity. Endocr Rev. 2022;43:654-77.
218. McKenna CF, Stierwalt HD, Zemski Berry KA, et al. Intramuscular diacylglycerol accumulates with acute hyperinsulinemia in insulin-resistant phenotypes. Am J Physiol Endocrinol Metab. 2024;327:E183-93.
219. Ramos-Jiménez A, Rubio-Valles M, Guereca-Arvizuo J, et al. Canonical and alternative pathways (insulin and exercise) of GLUT4 synthesis, signaling, intracellular clustering, and recruitment to the plasma membrane. Int J Mol Sci. 2026;27:3475.
220. Li H, Meng Y, He S, et al. Macrophages, chronic inflammation, and insulin resistance. Cells. 2022;11:3001.
221. Zhang Y, Pei Z, Wen Z, et al. Nuclear receptor-driven immunometabolic crosstalk: immune-centric pharmacology targeting the inflamed nexus. Front Cell Dev Biol. 2025;13:1706384.
222. Yu L, Qian J, Li X, et al. Insulin resistance: mechanisms and therapeutic interventions. Mol Biomed. 2026;7:12.
223. Ayer A, Fazakerley DJ, James DE, Stocker R. The role of mitochondrial reactive oxygen species in insulin resistance. Free Radic Biol Med. 2022;179:339-62.
224. Dimitriadis GD, Maratou E, Kountouri A, Board M, Lambadiari V. Regulation of postabsorptive and postprandial glucose metabolism by insulin-dependent and insulin-independent mechanisms: an integrative approach. Nutrients. 2021;13:159.
225. Habegger KM. Cross talk between insulin and glucagon receptor signaling in the hepatocyte. Diabetes. 2022;71:1842-51.
226. Marliss EB, Aoki TT, Unger RH, Soeldner JS, Cahill GF Jr. Glucagon levels and metabolic effects in fasting man. J Clin Invest. 1970;49:2256-70.
227. Bock G, Chittilapilly E, Basu R, et al. Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis. Diabetes. 2007;56:1703-11.
228. Rojas JM, Schwartz MW. Control of hepatic glucose metabolism by islet and brain. Diabetes Obes Metab. 2014;16:33-40.
229. Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol. 2017;13:572-87.
230. Capozzi ME, Coch RW, Koech J, et al. The limited role of glucagon for ketogenesis during fasting or in response to SGLT2 inhibition. Diabetes. 2020;69:882-92.
231. Smith K, Taylor GS, Peeters W, et al. Elevations in plasma glucagon are associated with reduced insulin clearance after ingestion of a mixed-macronutrient meal in people with and without type 2 diabetes. Diabetologia. 2024;67:2555-67.
232. De Feo P, Gallai V, Mazzotta G, et al. Modest decrements in plasma glucose concentration cause early impairment in cognitive function and later activation of glucose counterregulation in the absence of hypoglycemic symptoms in normal man. J Clin Invest. 1988;82:436-44.
233. Sprague JE, Arbelaez AM. Glucose counterregulatory responses to hypoglycemia. Pediatr Endocrinol Rev. 2011;9:463-73.
234. Cryer PE. Hierarchy of physiological responses to hypoglycemia: relevance to clinical hypoglycemia in type I (insulin dependent) diabetes mellitus. Horm Metab Res. 1997;29:92-6.
235. Beall C, Ashford ML, McCrimmon RJ. The physiology and pathophysiology of the neural control of the counterregulatory response. Am J Physiol Regul Integr Comp Physiol. 2012;302:R215-23.
236. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369:362-72.
237. Stanley S, Moheet A, Seaquist ER. Central mechanisms of glucose sensing and counterregulation in defense of hypoglycemia. Endocr Rev. 2019;40:768-88.
238. Ter Horst KW, Vatner DF, Zhang D, et al. Hepatic insulin resistance is not pathway selective in humans with nonalcoholic fatty liver disease. Diabetes Care. 2021;44:489-98.
239. Corkey BE. Banting lecture 2011: hyperinsulinemia: cause or consequence? Diabetes 2012;61:4-13.
240. Bergman RN. Pancreatic β cell function versus insulin resistance: application of the hyperbolic law of glucose tolerance. J Clin Invest. 2024;134:e176738.
241. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010;375:2267-77.
242. Aguer C, McCoin CS, Knotts TA, et al. Acylcarnitines: potential implications for skeletal muscle insulin resistance. FASEB J. 2015;29:336-45.
243. Zhang F, Pan X, Zhang X, Tong N. The effect of thiazolidinediones on body fat redistribution in adults: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2024;25:e13675.
245. Gonzalez-Cantero J, Martin-Rodriguez JL, Gonzalez-Cantero A, Arrebola JP, Gonzalez-Calvin JL. Insulin resistance in lean and overweight non-diabetic Caucasian adults: Study of its relationship with liver triglyceride content, waist circumference and BMI. PLoS One. 2018;13:e0192663.
246. Chen VL, Wright AP, Halligan B, et al. Body composition and genetic lipodystrophy risk score associate with nonalcoholic fatty liver disease and liver fibrosis. Hepatol Commun. 2019;3:1073-84.
247. Klein RJ, Viana Rodriguez GM, Rotman Y, Brown RJ. Divergent pathways of liver fat accumulation, oxidation, and secretion in lipodystrophy versus obesity-associated NAFLD. Liver Int. 2023;43:2692-700.
248. Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol. 2021;36:1497-507.
249. Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med. 2002;8:1376-82.
251. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004;29:1326-34.
252. Rhea EM, Leclerc M, Yassine HN, et al. State of the science on brain insulin resistance and cognitive decline due to Alzheimer’s disease. Aging Dis. 2024;15:1688-725.
253. Fan YH, Zhang S, Wang Y, Wang H, Li H, Bai L. Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease. Front Endocrinol. 2024;15:1494560.
254. Fajkić A, Lam YW, Jahić R, Ćavar I, Markotić A, Belančić A. From adipose dysfunction to multi-organ steatosis: defining the metabolic steatotic axis. Curr Issues Mol Biol. 2026;48:178.
255. Jensen MD, Caruso M, Heiling V, Miles JM. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes. 1989;38:1595-601.
256. Stumvoll M, Jacob S, Wahl HG, et al. Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in humans. J Clin Endocrinol Metab. 2000;85:3740-5.
257. Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol. 1981;240:E630-9.
258. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes. 1999;48:1198-214.
259. Kolb H, Stumvoll M, Kramer W, Kempf K, Martin S. Insulin translates unfavourable lifestyle into obesity. BMC Med. 2018;16:232.
260. Xourafa G, Korbmacher M, Roden M. Inter-organ crosstalk during development and progression of type 2 diabetes mellitus. Nat Rev Endocrinol. 2024;20:27-49.
261. Iglesias P. The endocrine role of hepatokines: implications for human health and disease. Front Endocrinol. 2025;16:1663353.
262. Pocai A, Lam TK, Gutierrez-Juarez R, et al. Hypothalamic K(ATP) channels control hepatic glucose production. Nature. 2005;434:1026-31.
263. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361-9.
264. Hemat Jouy S, Mohan S, Scichilone G, Mostafa A, Mahmoud AM. Adipokines in the crosstalk between adipose tissues and other organs: implications in cardiometabolic diseases. Biomedicines. 2024;12:2129.
265. Guria S, Hoory A, Das S, Chattopadhyay D, Mukherjee S. Adipose tissue macrophages and their role in obesity-associated insulin resistance: an overview of the complex dynamics at play. Biosci Rep. 2023;43:BSR20220200.
266. Mirabelli M, Misiti R, Sicilia L, et al. Hypoxia in human obesity: new insights from inflammation towards insulin resistance-a narrative review. Int J Mol Sci. 2024;25:9802.
268. Janssen JAMJL. The causal role of ectopic fat deposition in the pathogenesis of metabolic syndrome. Int J Mol Sci. 2024;25:13238.
269. Picó C, Palou M, Pomar CA, Rodríguez AM, Palou A. Leptin as a key regulator of the adipose organ. Rev Endocr Metab Disord. 2022;23:13-30.
270. Han Y, Sun Q, Chen W, et al. New advances of adiponectin in regulating obesity and related metabolic syndromes. J Pharm Anal. 2024;14:100913.
271. Al-Mansoori L, Al-Jaber H, Prince MS, Elrayess MA. Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance. Inflammation. 2022;45:31-44.
272. Sung HK, Doh KO, Son JE, et al. Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab. 2013;17:61-72.
273. Dulai AS, Min M, Sivamani RK. The gut microbiome’s influence on incretins and impact on blood glucose control. Biomedicines. 2024;12:2719.
274. Zhang S, Zhang Y, Li J, et al. Butyrate and propionate are negatively correlated with obesity and glucose levels in patients with type 2 diabetes and obesity. Diabetes Metab Syndr Obes. 2024;17:1533-41.
275. Wang Y, Liu J, Verbeke K, Retamal NG, Akkerman R, de Vos P. Dietary fiber and glucagon-like peptide-1 receptor agonists in obesity management: converging mechanisms, interactions, and strategies for durable weight control. Adv Nutr. 2026;17:100647.
276. Zeng Z, Chen M, Liu Y, et al. Role of Akkermansia muciniphila in insulin resistance. J Gastroenterol Hepatol. 2025;40:19-32.
277. Sun K, Gao Y, Wu H, Huang X. The causal relationship between gut microbiota and type 2 diabetes: a two-sample Mendelian randomized study. Front Public Health. 2023;11:1255059.
278. Del Cornò M, Aureli A, Varano B, Conti L. Endotoxins and metabolic endotoxemia in obesity and associated noncommunicable diseases: a focus on sex differences. Biomolecules. 2026;16:226.
279. He Y, Shaoyong W, Chen Y, et al. The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity. J Adv Res. 2026;80:351-70.
280. Alqahtani MS. The gut microbiota-metabolic axis: emerging insights from human and experimental studies on type 2 diabetes mellitus-a narrative review. Medicina. 2025;61:2017.
281. Hernández-Montoliu L, Rodríguez-Peña MM, Puig R, et al. A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass. Front Endocrinol. 2023;14:1181744.
282. Baroni I, Fabrizi D, Luciani M, et al. Probiotics and synbiotics for glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2024;43:1041-61.
283. Memon H, Abdulla F, Reljic T, et al. Effects of combined treatment of probiotics and metformin in management of type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2023;202:110806.
284. Wu Z, Zhang B, Chen F, et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: a randomized, controlled, prospective study. Front Cell Infect Microbiol. 2022;12:1089991.
285. Costes S, Bertrand G, Ravier MA. Mechanisms of beta-cell apoptosis in type 2 diabetes-prone situations and potential protection by GLP-1-based therapies. Int J Mol Sci. 2021;22:5303.
286. Khin PP, Lee JH, Jun HS. A brief review of the mechanisms of β-cell dedifferentiation in type 2 diabetes. Nutrients. 2021;13:1593.
287. Manduchi E, Descamps HC, Liu J, et al. Epigenetic adaptation of beta cells across lifespan and disease. Nat Metab. 2026;8:941-56.
288. Son J, Du W, Esposito M, et al. Genetic and pharmacologic inhibition of ALDH1A3 as a treatment of β-cell failure. Nat Commun. 2023;14:558.
289. Dorrell C, Schug J, Canaday PS, et al. Human islets contain four distinct subtypes of β cells. Nat Commun. 2016;7:11756.
290. Salem V, Silva LD, Suba K, et al. Leader β-cells coordinate Ca2+ dynamics across pancreatic islets in vivo. Nat Metab. 2019;1:615-29.
291. Johnston NR, Mitchell RK, Haythorne E, et al. Beta cell hubs dictate pancreatic islet responses to glucose. Cell Metab. 2016;24:389-401.
292. Wang J, Wen S, Chen M, et al. Regulation of endocrine cell alternative splicing revealed by single-cell RNA sequencing in type 2 diabetes pathogenesis. Commun Biol. 2024;7:778.
293. Lebowitz MR, Blumenthal SA. The molar ratio of insulin to C-peptide. An aid to the diagnosis of hypoglycemia due to surreptitious (or inadvertent) insulin administration. Arch Intern Med. 1993;153:650-5.
294. Nadeau KJ, Arslanian SA, Bacha F, et al. ; TODAY Study Group. Insulin clearance at randomisation and in response to treatment in youth with type 2 diabetes: a secondary analysis of the TODAY randomised clinical trial. Diabetologia. 2025;68:676-87.
295. Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13:15-28.
296. Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025;138:934-40.
297. Gavigan C, Donner T. Predictors of responsiveness to GLP-1 receptor agonists in insulin-treated patients with type 2 diabetes. J Diabetes Res. 2023;2023:9972132.
298. Zinman B, Wanner C, Lachin JM, et al. ; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28.
299. Neal B, Perkovic V, Mahaffey KW, et al. ; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57.
300. Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:422-34.
301. Rangaswami J, Bhalla V, de Boer IH, et al. ; American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Lifestyle and Cardiometabolic Health. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation. 2020;142:e265-86.
302. Herrington WG, Staplin N, Wanner C, et al. ; The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117-27.
303. Wu J, Li T, Guo M, et al. ; Clinical Group. Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue. Cell Discov. 2024;10:45.
304. Scholz H, Sordi V, Piemonti L. Cautious optimism warranted for stem cell-derived islet transplantation in type 2 diabetes. Transpl Int. 2024;37:13358.
305. Chong S, Lin M, Chong D, Jensen S, Lau NS. A systematic review on gut microbiota in type 2 diabetes mellitus. Front Endocrinol. 2024;15:1486793.
306. Ji H, Su S, Chen M, Liu S, Liu S, Guo J. The role of gut microbiota in insulin resistance: recent progress. Front Microbiol. 2025;16:1633029.
307. Zaidi S, Asalla S, Abdolahipour R, et al. Diminished CEACAM1 level plays a critical role in age-related hepatic fibrosis. Mech Ageing Dev. 2025;228:112122.
308. Sunjaya AP, Sunjaya AF. Targeting ageing and preventing organ degeneration with metformin. Diabetes Metab. 2021;47:101203.
309. Cortez BN, Pan H, Hinthorn S, et al. Heterogeneity of increased biological age in type 2 diabetes correlates with differential tissue DNA methylation, biological variables, and pharmacological treatments. Geroscience. 2024;46:2441-61.
310. Syed AR, Aloti RA, Awad BJ, et al. Cellular senescence and metabolic aging in type 2 diabetes: mechanistic insights and translational implications. Front Endocrinol. 2026;17:1799261.
311. Yan Q, Zhang H, Ma Y, et al. AQP1 mediates pancreatic β cell senescence induced by metabolic stress through modulating intracellular H2O2 level. Free Radic Biol Med. 2025;226:171-84.
312. Murakami T, Inagaki N, Kondoh H. Cellular senescence in diabetes mellitus: distinct senotherapeutic strategies for adipose tissue and pancreatic β cells. Front Endocrinol. 2022;13:869414.
313. Cha J, Aguayo-Mazzucato C, Thompson PJ. Pancreatic β-cell senescence in diabetes: mechanisms, markers and therapies. Front Endocrinol. 2023;14:1212716.
314. Suda M, Paul KH, Tripathi U, Minamino T, Tchkonia T, Kirkland JL. Targeting cell senescence and senolytics: novel interventions for age-related endocrine dysfunction. Endocr Rev. 2024;45:655-75.
315. Saliev T, Singh PB. Targeting senescence: a review of senolytics and senomorphics in anti-aging interventions. Biomolecules. 2025;15:860.
316. Palmer AK, Spinelli R, Prata LGL, et al. Senotherapeutics for metabolic disease and diabetic complications. J Intern Med. 2026;299:2-19.
317. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22:119-41.
319. Šešelja K, Šimunić E, Sobočanec S, et al. SIRT3-mediated mitochondrial regulation and driver tissues in systemic aging. Genes. 2025;16:1497.
320. Schultz MB, Sinclair DA. Why NAD+ declines during aging: it’s destroyed. Cell Metab. 2016;23:965-6.
321. Chini CCS, Cordeiro HS, Tran NLK, Chini EN. NAD metabolism: role in senescence regulation and aging. Aging Cell. 2024;23:e13920.
322. Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026;8:62-73.
323. Smith K, Deutsch AJ, McGrail C, et al. Multi-ancestry polygenic mechanisms of type 2 diabetes. Nat Med. 2024;30:1065-74.
324. Xia M, Li X. Updates of precision medicine in type 2 diabetes. Camb Prism Precis Med. 2023;1:e24.
325. Kraus WE, Bhapkar M, Huffman KM, et al. ; CALERIE Investigators. 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:673-83.
326. Iwasaki K, Abarca C, Aguayo-Mazzucato C. Regulation of cellular senescence in type 2 diabetes mellitus: from mechanisms to clinical applications. Diabetes Metab J. 2023;47:441-53.
